Intellipharmaceutics International Inc. (IPCI) Given a $8.00 Price Target by Brean Capital Analysts
Intellipharmaceutics International Inc. (NASDAQ:IPCI) received a $8.00 price objective from investment analysts at Brean Capital in a research report issued on Monday. The brokerage currently has a a “buy” rating on the stock. Brean Capital’s price objective indicates a potential upside of 181.69% from the stock’s previous close.
Several other research firms have also recently commented on IPCI. Maxim Group set a $6.00 target price on shares of Intellipharmaceutics International and gave the stock a “buy” rating in a research report on Thursday, October 6th. Zacks Investment Research raised shares of Intellipharmaceutics International from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Tuesday, September 13th.
Intellipharmaceutics International (NASDAQ:IPCI) traded down 7.04% during mid-day trading on Monday, reaching $2.64. 888,760 shares of the company’s stock traded hands. The company’s market capitalization is $75.89 million. The company has a 50-day moving average of $1.97 and a 200-day moving average of $1.84. Intellipharmaceutics International has a 52-week low of $1.41 and a 52-week high of $3.19.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/intellipharmaceutics-international-inc-ipci-given-a-8-00-price-target-by-brean-capital-analysts.html
Intellipharmaceutics International (NASDAQ:IPCI) last posted its earnings results on Wednesday, July 13th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. Intellipharmaceutics International had a negative net margin of 325.20% and a negative return on equity of 832.00%. Equities research analysts expect that Intellipharmaceutics International will post ($0.28) EPS for the current year.
A hedge fund recently bought a new stake in Intellipharmaceutics International stock. Atria Investments LLC purchased a new stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned about 0.27% of Intellipharmaceutics International as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.30% of the company’s stock.
Intellipharmaceutics International Company Profile
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.